medicina52巻13号

2015年12月発行

特集 抗血栓療法—おさえておきたい最新のエッセンス 抗血栓薬の特徴を知る 【抗血小板薬】

抗血小板薬（アセチルサリチル酸・ADP受容体阻害薬・シロスタゾール）の特徴

著者： 堀内久徳¹

所属機関： ¹東北大学加齢医学研究所基礎加齢研究分野

ページ範囲：P.2330 - P.2334

ポイント
●抗血小板薬として頻用されるアセチルサリチル酸（アスピリン^®）は，COX-1の非可逆的阻害薬であり，チエノピリジン誘導体はADP受容体P2Y₁₂の非可逆的阻害薬である．
●アセチルサリチル酸とチエノピリジン誘導体は虚血性イベント発症を予防するが，出血性合併症の増加は避けられず，両者を考慮して適応症例を選択すべきである．
●シロスタゾールはPDE3阻害薬であり，血管拡張作用および抗血小板作用をもつ．

参考文献

1）Antithrombotic Trialists' Collaboration：Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324：71-86, 2002

2）Antithrombotic Trialists'（ATT）Collaboration, Baigent C, et al：Aspirin in the primary and secondary prevention of vascular disease；Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373：1849-1860, 2009

3）Diener HC, et al：Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients（MATCH）；Randomised, double-blind, placebo-controlled trial. Lancet 364：331-337, 2004

4）Bhatt DL, et al：Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354：1706-1717, 2006

5）Bhatt DL, et al：Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49：1982-1988, 2007

6）Harbison JW：Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 23：1723-1727, 1992

7）CAPRIE Steering Committee：A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events（CAPRIE）. Lancet 348：1329-1339, 1996

8）Jinnai T, et al：Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 73：1498-1503, 2009

9）堀内久徳：抗血小板薬の遺伝薬理学—ADP受容体拮抗約の薬効に影響する遺伝子多型・日本人と欧米人の人種差—．血液フロンティア25：81-89, 2015

10）Wiviott SD, et al：Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357：2001-2015, 2007

11）Yokoi H, et al：Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thrombosis Research 129：623-628, 2012

12）Saito S, et al：Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome；The PRASFIT-ACS study. Circ J 78, 1684-1692, 2014

13）Isshiki T, et al：Prasugrel, a third-generation P2Y receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78：2926-2934, 2014

14）Gotoh F, et al：Cilostazol stroke prevention study；A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9：147-157, 2000

15）Shinohara Y, et al：Cilostazol for prevention of secondary stroke（CSPS 2）；An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9：959-968, 2010